Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Transplant Recipients Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates

NCT03811873
View directory record Official record
Conditions
Metabolic Bone Disease, Transplant-Related Disorder, Secondary Osteoporosis
Interventions
Dual x-ray absorptiometry, Vertebral Fracture Assessment
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jun 10, 2026, 2:05 PM EDT
Active, not recruiting Not applicable Interventional

Health Advocate for Children After Liver Transplant

NCT07279350
View directory record Official record
Conditions
Pediatric Liver Transplanted Recipients
Interventions
Health advocate, Enhanced Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
0 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")

NCT01552369
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Jun 10, 2026, 2:05 PM EDT
Withdrawn Not applicable Interventional

mDOT for Immunosuppressant Adherence in Adolescent Liver Transplant Recipients

NCT03781830
View directory record Official record
Conditions
Medication Adherence, Liver Transplantation
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients

NCT01128335
View directory record Official record
Conditions
Liver Transplantation
Interventions
MMF(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

NCT02118896
View directory record Official record
Conditions
Heart Transplantation, Liver Transplantation, Kidney Transplantation
Interventions
FK506E
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jun 10, 2026, 2:05 PM EDT
Recruiting Not applicable Interventional

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

NCT05613010
View directory record Official record
Conditions
Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication, Adherence, Patient, Adherence, Treatment
Interventions
mHealth Messaging Intervention Group
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 10, 2026, 2:05 PM EDT
Terminated No phase listed Observational

Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients

NCT06263114
View directory record Official record
Conditions
Liver Transplant; Complications, Liver Failure, Acute
Interventions
TruGraf® Liver gene expression panel (GEP)
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Starzl Network Patient Reported Outcomes

NCT05241847
View directory record Official record
Conditions
Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
Interventions
PeLTQL delivery via electronic means
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 10, 2026, 2:05 PM EDT
Completed No phase listed Observational

HIV-to-HIV Transplant at MGH

NCT02750397
View directory record Official record
Conditions
HIV, Awaiting Organ Transplant
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jun 10, 2026, 2:05 PM EDT
Enrolling by invitation No phase listed Observational

Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant

NCT05224583
View directory record Official record
Conditions
Polyomavirus Infections, BK Viremia, Liver Transplant Infection, Kidney Transplant Infection
Interventions
Simultaneous Liver-Kidney Transplant
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Timeline
2021 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 10, 2026, 2:05 PM EDT
Active, not recruiting No phase listed Observational

Molecular Assessment and Profiling of Liver Transplant Recipients

NCT04793360
View directory record Official record
Conditions
Liver Transplantation, Biomarkers
Interventions
LiverCare
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

NCT03819322
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 2:05 PM EDT
Completed No phase listed Observational

Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers

NCT00857844
View directory record Official record
Conditions
Complication of Transplanted Liver
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 4 Interventional

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

NCT00001107
View directory record Official record
Conditions
Candidiasis
Interventions
Fluconazole, AmBisome
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

NCT00286871
View directory record Official record
Conditions
Chronic Hepatitis C, Organ Transplantation, Immunosuppression
Interventions
Neoral, Tacrolimus
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

NCT00135694
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions
calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal
Drug · Procedure · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Jun 10, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

NCT02630563
View directory record Official record
Conditions
Pediatric Liver Transplantation
Interventions
Corticosteroids, Cyclosporine, mycophenolate mofetil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 12 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jun 10, 2026, 2:05 PM EDT
Withdrawn No phase listed Observational

Evaluation of Kidney Disease in Liver Transplant Recipients

NCT00585429
View directory record Official record
Conditions
Kidney Disease, Liver Transplantation
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jun 10, 2026, 2:05 PM EDT
Withdrawn Not applicable Interventional

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

NCT03046901
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions
Vancomycin
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Jun 10, 2026, 2:05 PM EDT
Terminated No phase listed Observational

An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study

NCT00371605
View directory record Official record
Conditions
Liver Transplant, Fungal Infection
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Jun 10, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional

Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection

NCT01560468
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
ITX 5061
Drug
Lead sponsor
Schiano, Thomas D., MD
Other
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jun 10, 2026, 2:05 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

NCT03702218
View directory record Official record
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Not applicable Interventional Results available

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

NCT00336817
View directory record Official record
Conditions
Immunosuppression
Interventions
Myfortic, CellCept
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jun 10, 2026, 2:05 PM EDT